GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today that the Company has amended and extended its existing Collaborative Research, Development and Supply Agreement with the PATH Malaria Vaccine Initiative (MVI). This Amendment includes up to $750,000 in additional funding through the end of 2007, to continue advancing a new multivalent malaria vaccine towards clinical evaluation.
